Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Spartalizumab |
Indication/Tumor Type | anaplastic thyroid carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | anaplastic thyroid carcinoma | predicted - sensitive | Spartalizumab | Phase II | Actionable | In a Phase II trial, Spartalizumab (PDR001) was tolerated in patients with anaplastic thyroid carcinoma, and resulted in an overall response rate (ORR) of 19% (8/42, 3 complete responses, 5 partial responses), median progression-free survival of 1.7 mo, and median overall survival of 5.9 mo; ORR was higher in patients with tumor PD-L1 >=1% compared to PD-L1<1% (29%, 8/28 vs 0%, 0/12, p=0.079), and highest ORR (35%) was observed in patients with PD-L1 >= 50% (PMID: 32364844; NCT02404441). | 32364844 |
PubMed Id | Reference Title | Details |
---|---|---|
(32364844) | PD-1 Blockade in Anaplastic Thyroid Carcinoma. | Full reference... |